What medications should be prescribed after a Rejuran (polynucleotide) injection procedure?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: September 29, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Post-Rejuran Procedure Management

Routine antibiotic prophylaxis is not indicated after Rejuran (polynucleotide) injection procedures. Based on established surgical antibiotic prophylaxis guidelines, simple intradermal injections do not require antibiotics, and the available evidence shows Rejuran has a favorable safety profile with no documented cases of infection requiring prophylactic coverage 1, 2.

Standard Post-Procedure Protocol

Medications to Prescribe

None routinely required. The evidence supports a minimalist approach:

  • No prophylactic antibiotics: Rejuran injections are analogous to other intradermal procedures (like intravitreal injections or dermal fillers) which explicitly do not require antibiotic prophylaxis 1
  • No anti-inflammatory agents: The procedure itself has anti-inflammatory properties through A2A receptor activation 3
  • Symptomatic management only: Consider over-the-counter analgesics (acetaminophen or ibuprofen) if patient experiences injection-site discomfort

Post-Procedure Care Instructions

Conservative wound care is sufficient:

  • Keep injection sites clean and dry for 24 hours
  • Avoid makeup application for 24 hours
  • Avoid excessive heat exposure (saunas, hot yoga) for 48 hours
  • Gentle cleansing with mild soap and water after 24 hours
  • No massage or manipulation of treated areas for 48 hours

When to Consider Additional Treatment

High-Risk Scenarios Requiring Modified Approach

Only prescribe antibiotics if specific risk factors are present:

  1. Contaminated injection environment or breach of sterile technique during procedure
  2. Immunocompromised patients (active chemotherapy, high-dose corticosteroids >20mg prednisone daily, transplant recipients)
  3. Pre-existing skin infection at or near injection site
  4. Signs of early infection developing post-procedure (increasing erythema beyond 48 hours, purulent drainage, fever)

If antibiotics are warranted in these exceptional cases, use:

  • First-line: Cephalexin 500mg PO QID for 5-7 days (covers Staphylococcus aureus and Streptococcus)
  • Penicillin allergy: Clindamycin 300mg PO TID for 5-7 days

Adjunctive Polynucleotide Use

Consider additional PN sessions for wound complications:

The evidence demonstrates PN's utility when complications arise 4, 5, 6:

  • Delayed healing: Additional PN at 8-hour to 2-week intervals depending on severity
  • Early ischemic changes: Immediate PN administration (q8h×4 sessions showed efficacy) 4
  • Unexpected tissue compromise: PN appears safe and may accelerate recovery 5

Common Pitfalls to Avoid

  1. Over-prescribing antibiotics: The 2019 surgical prophylaxis guidelines emphasize that brief procedures without implanted material do not require antibiotics 1. Unnecessary antibiotic use increases resistance and adverse events without improving outcomes.

  2. Extending prophylaxis beyond 24 hours: Even when antibiotics are indicated, duration should never exceed 48 hours and is typically limited to the procedural period 1

  3. Confusing normal post-injection inflammation with infection: Expected findings include mild erythema, edema, and tenderness for 24-48 hours. True infection presents with progressive worsening after 48-72 hours, purulence, or systemic symptoms.

  4. Prescribing topical antibiotics: No evidence supports topical antibiotic use for intradermal aesthetic procedures and may increase sensitization risk

Evidence Quality Note

The antibiotic prophylaxis recommendations are based on high-quality 2019 guidelines from established surgical societies [1-1. The Rejuran-specific safety data comes from recent clinical studies (2025-2026) consistently showing favorable safety profiles with no documented infectious complications requiring prophylaxis [4-7. The convergence of these evidence sources supports a conservative, non-antibiotic approach for routine cases.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.